Study on ISM6331 for Patients with Advanced Mesothelioma or Other Advanced Solid Tumors

Inclusion Criteria

• Adults aged 18 or older.
• Diagnosed with advanced or metastatic mesothelioma or other solid tumors that cannot be surgically removed and have not responded to standard treatments.
• For Part 2, patients with solid tumors other than mesothelioma must show genetic changes in the Hippo signaling pathway.
• Patients with mesothelioma must have previously received immune checkpoint therapy and platinum-based chemotherapy.
• Must have at least one tumor that can be evaluated or measured by scans.
• Must be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Expected to live at least 12 more weeks.
• Have adequate organ function based on medical tests.
• Able to understand and sign a consent form agreeing to participate in the study.

Exclusion Criteria

• Have previously been treated with a TEAD inhibitor.
• Participated in another clinical trial or received anti-tumor therapy within the last 28 days or 5 half-lives of the drug.
• Have an active brain tumor or untreated cancer spread to the brain.
• Have severe or uncontrolled health conditions as judged by the study doctor.
• Unable to take oral medication or have a digestive condition that affects drug absorption.
• Have any significant health issues that could interfere with the study or affect the drug's processing in the body.
• Currently taking certain medications that affect drug metabolism and cannot be stopped before starting the study.